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Abstract 1K,25-Dihydroxyvitamin D3 (1,25-(OH)2-D3), the
active metabolite of vitamin D, can inhibit NF-UB activity in
human MRC-5 fibroblasts, targeting DNA binding of NF-UB but
not translocation of its subunits p50 and p65. The partial
inhibition of NF-UB DNA binding by 1,25-(OH)2-D3 is
dependent on de novo protein synthesis, suggesting that 1,25-
(OH)2-D3 may regulate expression of cellular factors which
contribute to reduced DNA binding of NF-UB. Although NF-UB
binding is decreased by 1,25-(OH)2-D3 in MRC-5 cells, IL-8 and
IL-6 mRNA levels are only moderately downregulated, demon-
strating that inhibition of NF-UB DNA binding alone is not
sufficient for optimal downregulation of these genes.
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1. Introduction
1K,25-Dihydroxyvitamin D3 (1,25-(OH)2-D3 ; calcitriol), the
hormonally active form of vitamin D, is a potent regulator of
calcium and skeletal homeostasis which also exerts other ac-
tivities, including induction of di¡erentiation and inhibition of
proliferation in various cell systems [1]. 1,25-(OH)2-D3 exerts
its e¡ects by binding to its nuclear receptor, the vitamin D
receptor (VDR), a member of the superfamily of nuclear re-
ceptors [2]. Like several of these receptors, VDR has been
shown to bind as a heterodimer with the retinoid X receptor
(RXR) to DNA sequences called vitamin D response elements
(VDRE) [3^6].
1,25-(OH)2-D3 also has immunomodulatory properties [7]
and can downregulate the expression of some cytokines. At
the molecular level, VDR has been shown to inhibit the ac-
tivity of the transcription factor complex AP-1 on the osteo-
calcin promoter [8]. 1,25-(OH)2-D3 has also been shown to
repress IL-2 gene expression in T lymphocytes by inhibiting
complex formation between nuclear factor of activated T cells
(NFATp) and AP-1 at the NFAT binding site of the IL-2
promoter. In vitro analysis has shown that VDR can bind
as a VDR/RXR heterodimer to the NFAT binding site of
the IL-2 promoter [9,10]. Another transcription factor which
can be a¡ected by 1,25-(OH)2-D3 is nuclear factor-UB
(NF-UB). NF-UB is an inducible transcription factor, repre-
senting a family of related proteins including p50 (NF-UB1),
p52 (NF-UB2), p65 (RelA), c-Rel and RelB. NF-UB plays an
essential role in the transcriptional regulation of in£ammatory
genes, such as IL-8, IL-6, ICAM-1, E-selectin and IFN-L [11^
14]. NF-UB is bound in the cytosol to inhibitor proteins,
members of the IUB family. Phosphorylation of IUB after
cell activation is associated with release of NF-UB which
then translocates to the nucleus [15^19].
1,25-(OH)2-D3 has been reported to downregulate the levels
of the NF-UB protein p50 and its precursor p105 in human
lymphocytes [20]. We have shown in a previous report that
TNF-K-induced IL-8 gene expression is repressed in a human
melanoma cell line by 1,25-(OH)2-D3 at the transcriptional
level, involving the NF-UB binding site of the IL-8 promoter
[21]. NF-UB is further involved in the downregulation of IL-
12 expression by 1,25-(OH)2-D3 in human monocytes and
dendritic cells [22]. In addition to its classical therapeutic ef-
fects, 1,25-(OH)2-D3 may therefore be of interest as an anti-
in£ammatory principle. Since ¢broblasts, which can play a
major role in in£ammatory processes, have readily inducible
NF-UB activity and express high levels of IL-8, we investi-
gated whether NF-UB is a target of 1,25-(OH)2-D3 in this
cell type. In contrast to the glucocorticoid dexamethasone,
1,25-(OH)2-D3 caused a partial inhibition of cytokine-induced
NF-UB DNA binding in these cells, an e¡ect which appears
not mediated by VDR directly, but rather via other cellular,
1,25-(OH)2-D3-inducible factors.
2. Materials and methods
2.1. Materials
1,25-(OH)2-D3 was obtained from Calbiochem (La Jolla, CA). Dex-
amethasone was purchased from Sigma (St. Louis, MO) and stored as
a 1 mM stock in methanol at 320‡C. Recombinant human TNF-K
(2U107 U/mg) was purchased from Genzyme (Cambridge, MA). Re-
combinant human IL-1L was from P. Ramage (Novartis Pharma,
Basel).
2.2. Cell culture
Normal human embryonic lung ¢broblasts MRC-5 cells were pur-
chased from ATCC (Rockville, MD). Cells were cultivated in MEM
supplemented with 10% FCS in an humidi¢ed 5% CO2 atmosphere,
and were kept for no longer than 15 passages.
2.3. Immuno£uorescence
7U104 cells were seeded into each well of eight-well LabTek slides
(Nunc, Naperville, IL) and treated as described in the text. Cells were
¢xed with 4% paraformaldehyde for 10 min, permeabilized with 0.5%
Triton X-100 for 5 min, and then incubated for 1 h with a rabbit
polyclonal antibody against NF-UB p65 or a goat polyclonal antibody
against NF-UB p50 (both from Santa Cruz Biotechnology, Santa
Cruz, CA) at room temperature. Detection was carried out using a
rhodamine-conjugated goat anti-rabbit antibody (Accurate Scienti¢c,
Westbury, NY) or a £uorescein isothiocyanate-coupled anti-goat IgG
(Santa Cruz Biotechnology). The slides were examined with a Bio-
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Fig. 1. Binding of NF-UB to its binding site in the IL-8 promoter is decreased by 1,25-(OH)2-D3 but not dexamethasone. a: 2U106 cells were
treated with IL-1L (50 ng/ml) for 1 h before preparation of nuclear extracts. For EMSA, about 5 Wg of the extracts were incubated with 0.4 ng
radiolabeled oligonucleotide (IL-8 wt NF-IL-6/NF-UB). 100-fold molar excess of unlabeled oligonucleotides was used for competition. For
supershift analysis, 2 Wl of anti-p65 or anti-C/EBPL antibody was added to the binding reaction and kept at room temperature for 20 min prior
to addition of poly dI.dC and the radiolabeled IL-8 wt NF-IL-6/NF-UB oligonucleotide. b: Nuclear extracts from IL-1L-stimulated MRC-5
cells were incubated with 2 Wl of anti-p50 (rabbit), 2 Wl anti-p52, 2 Wl anti-c-Rel or 2 Wl anti-RelB antibody for 20 min at room temperature
prior to addition of poly dI.dC and radiolabeled IL-8 wt NF-IL-6/NF-UB oligonucleotide. c: The same extract was incubated with 2 Wl of anti-
p50 (goat) antibody, com¢rming the presence of p50 in the complex. d: 2U106 cells were treated with 1,25-(OH)2-D3 (20 nM), dexamethasone
(1 WM) or both for 23 h before stimulation with either TNF-K (200 U/ml) or IL-1L (50 ng/ml) for 1 h. Controls were treated with vehicle only
(0.1% ethanol), TNF-K or IL-1L alone. EMSAs were performed with nuclear extracts incubated with the IL-8 wt NF-IL-6/NF-UB radiolabeled
oligonucleotide. The decrease in NF-UB DNA binding by 1,25-(OH)2-D3 was observed in at least ¢ve individual preparations.
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Rad MRC 600 confocal laser scanning microscope (Bio-Rad, Hemel
Hempstead, UK), mounted on a Zeiss IM 10 microscope (Zeiss, Vien-
na, Austria).
2.4. Electrophoretic mobility shift assays
For electrophoretic mobility shift assay (EMSA) experiments
the following oligonucleotides were used: IL-8 wt NF-IL-6/NF-UB:
5P-AATTCCAGTTGCAAATCGTGGAATTTCCTG-3P, IL-8 NF-UB
mutant: 5P-AATTCCAGTTGCAAATCGTGGCCGGTCCTG-3P ;
IL-8 NF-IL-6 mutant: 5P-AATTCCAGCTACGAGTCGTGGAATT-
TCCTG-3P ; p50 NF-UB: 5P-GATCTCGACGTCAGTGGGAATTT-
CCAG-3P ; IL-6 NF-UB: 5P-GATCTATGTGGGATTTTCCCATG-
3P ; HIV LTR NF-UB: 5P-GATCTTGTTACAAGGGACTTTCCGC-
G-3P. Nuclear extracts and EMSA experiments were performed as
described previously [23]. All antibodies for supershift experiments
were from Santa Cruz (Santa Cruz, CA).
2.5. Isolation of RNA and Northern analysis
MRC-5 cells were seeded at a density of 5U105 cells per well of a
six-well plate and allowed to attach overnight. On the next day, cells
were treated as described in the text. Total RNA was prepared using
the Ultraspec RNA isolation reagent (Biotecx Laboratories, Houston,
TX). Northern blot analyses were performed as previously described
[23]. IL-8 was detected using a 350 bp fragment comprising the coding
region of the IL-8 cDNA. IL-6 cDNA was kindly provided by R.
Movva (Novartis Pharma, Basel). Glyceraldehyde 3-phosphate dehy-
drogenase was detected using a EcoRI-HindIII fragment of the rat
cDNA, kindly provided by P. Amstad (ISREC, Lausanne).
3. Results
3.1. Binding of NF-UB to its binding site in the IL-8 promoter
is decreased by 1,25-(OH)2-D3 but not dexamethasone in
MRC-5 human ¢broblasts
EMSA using nuclear extracts from MRC-5 cells stimulated
with IL-1L for 1 h revealed a single complex with a labeled
oligonucleotide representing the nucleotides 394 to 371 rel-
ative to the transcription start of the IL-8 gene, containing the
nuclear factor for interleukin-6 (NF-IL-6) and NF-UB binding
sites of the IL-8 promoter (IL-8 wt NF-IL-6/NF-UB). Com-
petition experiments, using 100-fold molar excess of unlabeled
oligonucleotides comprising mutated sequences (IL-8 NF-UB
mutant, IL-8 NF-IL-6 mutant) and supershift experiments
using antibodies directed against the NF-UB subunit p65
and CAAT/enhancer binding protein L (C/EBPL/NF-IL-6),
demonstrated that this binding occurs speci¢cally on the
NF-UB binding site of the IL-8 promoter and does not involve
C/EBPL/NF-IL-6 (Fig. 1a). To determine whether the com-
plex contains a p65 homodimer or whether other NF-UB pro-
teins are involved, supershift experiments were performed us-
ing antibodies directed against the NF-UB proteins p50, p52,
c-Rel and RelB. Although the antibody against p50 did not
apparently shift the complex, binding to the radiolabeled oli-
gonucleotide was reduced (Fig. 1b). Similar results were ob-
tained with a di¡erent anti-p50 antibody (Fig. 1c), indicating
that the observed complex contains a p50/p65 heterodimer.
Stimulation with TNF-K for 1 h also induced NF-UB com-
plex formation in MRC-5 cells, but preincubation of cells with
1,25-(OH)2-D3 for 23 h reduced this binding. Treatment of
cells with 1,25-(OH)2-D3 for 23 h followed by a 1 h stimula-
tion with IL-1L resulted in a signi¢cant reduction of NF-UB
binding compared to that induced by IL-1L alone. In contrast,
pretreatment of cells with 1 WM dexamethasone for 23 h pre-
ceding a 1 h stimulation with either IL-1L or TNF-K did not
reduce NF-UB binding to the IL-8 promoter sequence. There
was even an enhanced binding of the IL-1L-induced NF-UB
complex observed when cells were prestimulated with dexame-
thasone, which also partially restored the reduced NF-UB
binding by 1,25-(OH)2-D3 (Fig. 1d). These results indicate
that 1,25-(OH)2-D3 has an activity on NF-UB which is distinct
from that of dexamethasone.
3.2. Reduction of NF-UB binding requires de novo protein
synthesis
Cells were treated with the protein synthesis inhibitor cyclo-
heximide (CHX; 5 Wg/ml) alone or simultaneously with 1,25-
(OH)2-D3 before IL-1L stimulation for 1 h. EMSA studies
showed that 23 h pretreatment with CHX had no e¡ect on
IL-1L-induced binding of NF-UB to the oligonucleotide (IL-8
wt NF-IL-6/NF-UB). However, when cells were simultane-
ously exposed to CHX and 1,25-(OH)2-D3, no reduction in
IL-1L-induced NF-UB complex formation was seen. This
CHX-mediated inhibition of 1,25-(OH)2-D3 action suggests
that reduction of NF-UB DNA binding by 1,25-(OH)2-D3
requires de novo protein synthesis in MRC-5 cells (Fig. 2).
3.3. Reduction of NF-UB binding by 1,25-(OH)2-D3 is not
restricted to the IL-8 promoter NF-UB binding site
Further EMSA experiments were performed to investigate
whether the repression of NF-UB binding occurs on NF-UB
binding sites other than that in the IL-8 promoter. Nuclear
extracts were incubated with radiolabeled oligonucleotides
representing the NF-UB binding site of the human immuno-
de¢ciency virus long terminal repeat (HIV-LTR), the NF-UB
binding site of the p50 promoter at nucleotides 311 to 32
relative to the transcription start [24] and the NF-UB binding
site of the IL-6 promoter. In all cases the binding of NF-UB
was reduced in nuclear extracts from cells preincubated with
1,25-(OH)2-D3 before treatment with IL-1L, showing that this
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Fig. 2. Reduction of NF-UB binding requires de novo protein syn-
thesis. 2U106 cells were treated with 1,25-(OH)2-D3 (20 nM) for
23 h preceding a 1 h stimulation with IL-1L (50 ng/ml) or treated
simultaneously with cycloheximide (CHX; 5 Wg/ml) and 1,25-(OH)2-
D3 (20 nM) for 23 h before stimulation with IL-1L for 1 h. Con-
trols were treated with vehicle (0.1% ethanol), for 23 h with CHX
plus vehicle or CHX with an additional stimulation for 1 h with
IL-1L. EMSAs were performed with nuclear extracts incubated with
the IL-8 wt NF-IL-6/NF-UB radiolabeled oligonucleotide.
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phenomenon is not restricted to the IL-8 NF-UB binding site
(Fig. 3).
3.4. Cytokine-induced IL-8 and IL-6 mRNA levels are
down-regulated by 1,25-(OH)2-D3 and dexamethasone
in MRC-5 ¢broblasts
Northern blot experiments demonstrated that stimulation
of MRC-5 cells with IL-1L (50 ng/ml) for 4 h resulted in
induction of IL-8 mRNA and, at lower levels, IL-6 mRNA.
When cells were preincubated for 20 h with 1,25-(OH)2-D3 or
dexamethasone, or a combination of both before 4 h stimu-
lation with IL-1L, a reduction of IL-1L-induced IL-8 mRNA
levels was observed (Fig. 4a). IL-1L-induced IL-6 mRNA lev-
els were moderately reduced by 1,25-(OH)2-D3, while dexa-
methasone had a more pronounced e¡ect (Fig. 4b). TNF-K
induced much lower levels of IL-8 mRNA in MRC-5 cells
than IL-1L, while induction of IL-6 mRNA by TNF-K was
almost undetectable. This observation is consistent with the
¢ndings of Ng et al. who reported that IL-6 and IL-8 mRNA
levels are di¡erentially regulated by TNF-K and IL-1L in the
human ¢broblast cell lines MRC-9 and FS-4. The higher in-
duction of IL-6 and IL-8 mRNA by IL-1L is due to enhanced
transcription rates and mRNA stability induced by IL-1L
compared to TNF-K [25]. However, treatment of MRC-5 cells
with 1,25-(OH)2-D3 (20 nM), dexamethasone (1 WM) or both
caused a reduction of TNF-K-induced IL-8 mRNA levels in
all cases (Fig. 4a).
3.5. Translocation of p50 and p65 is not inhibited by
1,25-(OH)2-D3 in MRC-5 cells
Immuno£uorescence analysis was performed using MRC-5
cells treated with either 1,25-(OH)2-D3 (20 nM), dexametha-
sone (1 WM) or a combination of both for 23 h preceding a 1 h
stimulation with IL-1L (50 ng/ml). Staining of cells for p50 or
p65 demonstrated translocation of both NF-UB subunits to
the nucleus induced by 1 h treatment with IL-1L, but neither
1,25-(OH)2-D3 nor dexamethasone signi¢cantly altered this
translocation (Fig. 5).
4. Discussion
Chronic in£ammatory diseases, such as psoriasis or rheu-
matoid arthritis, are characterized by dysregulation of expres-
sion of chemotactic peptides, triggering leukocyte in¢ltration
into the in£amed tissue [26^28]. Clinically such chronic disor-
ders can be treated with antiin£ammatory compounds, which
act via inhibition of proin£ammatory and chemotactic cyto-
kines, such as IL-8.
The sequences 394 to 371 relative to the transcription start
of the IL-8 gene have been shown to be essential for both
activation and repression of the IL-8 promoter by various
agents [29^36], mainly involving the transcription factor NF-
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Fig. 4. Cytokine-induced IL-8 and IL-6 mRNA levels are downregulated by 1,25-(OH)2-D3 or dexamethasone in MRC-5 cells. 5U105 cells
were seeded into each well of a six-well plate and treated with 1,25-(OH)2-D3 (D3, 20 nM), dexamethasone (dex, 1 WM), 1,25-(OH)2-D3 and
dexamethasone for 20 h before stimulation with either TNF-K (200 U/ml) or IL-1L (50 ng/ml) for 4 h. Total RNA was isolated and about 10
Wg of each total RNA was loaded onto an agarose-formaldehyde gel. After transfer, the blots were hybridized with a 32P-labeled human IL-8
cDNA probe (a) or a 32P-labeled human IL-6 cDNA probe (b) at 65‡C overnight. Blots were exposed to X-ray ¢lms at 370‡C for 4 h (IL-8)
and 24 h (IL-6). After stripping the same blots were rehybridized with a 32P-labeled rat GAPDH cDNA probe.
Fig. 3. Reduction of NF-UB binding by 1,25-(OH)2-D3 is not re-
stricted to the IL-8 promoter NF-UB binding site. 2U106 cells were
treated with 1,25-(OH)2-D3 (20 nM) for 23 h preceding a 1 h stimu-
lation with IL-1L (50 ng/ml) or with IL-1L alone. For EMSAs, nu-
clear extracts were incubated with radiolabeled oligonucleotides rep-
resenting one NF-UB binding site of the p50 promoter (p50 NF-
UB), the NF-UB binding site of the HIV long terminal repeat (HIV-
LTR NF-UB) or the NF-UB binding site of the IL-6 promoter (IL-6
NF-UB).
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UB. A classical repressor of NF-UB-driven genes, such as IL-8,
is the glucocorticoid dexamethasone, which mediates its ef-
fects via the glucocorticoid receptor (GR). One mechanism
for glucocorticoid inhibition of in£ammatory cytokine expres-
sion is GR-NF-UB interaction, which has been reported to
occur at di¡erent levels, either directly with the p65 subunit
of NF-UB [37^41] or via upregulation of its inhibitor IUBK,
which then retains NF-UB in the cytoplasm [42^45]. In con-
trast to glucocorticoids, the e¡ects of 1,25-(OH)2-D3 on NF-
UB activity have not been well studied, and the mechanism is
less clear. Yu et al. have shown that 1,25-(OH)2-D3 can re-
duce levels of p50 and its precursor p105 in human lympho-
cytes and they observed reduced binding of PMA-induced
nuclear factors to the NF-UB binding site of the IL-6 pro-
moter [20]. We have previously shown that 1,25-(OH)2-D3
downregulates TNF-K-induced IL-8 promoter activity in the
human melanoma cell line G-361, accompanied by reduced
binding of NF-UB [21]. It was further demonstrated that
1,25-(OH)2-D3 can transcriptionally downregulate expression
of the p40 subunit of IL-12, and requires the presence of VDR
and RXR [22]. To establish whether 1,25-(OH)2-D3 could be a
potentially useful antiin£ammatory agent and to evaluate its
role in NF-UB regulation, we investigated its e¡ect in ¢bro-
blasts, which have been shown to contribute to disease proc-
esses by production of in£ammatory cytokines [46]. We dem-
onstrate here that 1,25-(OH)2-D3 can partially inhibit the
activity of NF-UB in MRC-5 normal human ¢broblasts.
While translocation of its subunits p50 and p65 is not a¡ected
by 1,25-(OH)2-D3, its major activity is inhibition of the DNA
binding of NF-UB, which we observed on a variety of NF-UB
binding sites and which appears not to be mediated directly by
VDR. Similar results were also obtained by D’Ambrosio et al.
who showed partial inhibition of NF-UB DNA binding by
1,25-(OH)2-D3 in THP-1 human monocytic cells [22].
Although activation of NF-UB plays a fundamental role in
the transcription of IL-8 and IL-6, mRNA levels of these
cytokines are only moderately downregulated by 1,25-
(OH)2-D3. We conclude that reduction of NF-UB binding
by 1,25-(OH)2-D3 is not su⁄cient to strongly repress expres-
sion of these genes in MRC-5 cells and that additional events,
such as interference with the transactivation potential of NF-
UB or interaction with other nuclear factors, are required for
optimal repression of IL-8 or IL-6 transcription. However,
enhancement of mRNA stability by IL-1 may counteract reg-
ulatory events which occur at the level of transcription.
The mechanism by which 1,25-(OH)2-D3 reduces NF-UB
binding does not appear to involve direct protein-protein in-
teraction of NF-UB and VDR of the type reported for the
GR, but requires protein synthesis, as cycloheximide abro-
gated the negative e¡ect of 1,25-(OH)2-D3. Also, recombinant
human VDR and RXRK themselves were unable to bind the
NF-UB binding site or to compete NF-UB from its site in the
IL-8 promoter (data not shown), observations consistent with
the ¢ndings of D’Ambrosio et al. [22]. It may therefore be
possible that 1,25-(OH)2-D3 can upregulate expression of an-
other factor(s), which then contribute to the inhibition of NF-
UB binding.
The ability of 1,25-(OH)2-D3 to inhibit NF-UB activity in
cell types involved in in£ammation clearly contributes to the
notion of 1,25-(OH)2-D3 as an antiin£ammatory principle,
and supports clinical use of 1,25-(OH)2-D3 either alone or
in combination with ‘classical’ inhibitors of in£ammation. Fu-
ture studies will therefore focus on this activity of 1,25-(OH)2-
D3 and on synthetic analogs, which may have more pro-
nounced activity than the parent hormone.
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